Table 4.
Treatment outcomes of expansion cohort (n = 17).
| Cohort | Subject # | Disease type | DLT | Best response | Duration of treatment (days) |
|---|---|---|---|---|---|
| 20 mg/kg | RB001 | Ovarian cancer | None | PD | 28.0 |
| RB002 | Ovarian cancer | None | PD | 14.0 | |
| RB003 | Ovarian cancer | None | PD | 14.0 | |
| RB004 | Ovarian cancer | None | SD | 147.0 | |
| RB005 | Ovarian cancer | None | PD | 30.0 | |
| RB006 | Ovarian cancer | None | PD | 14.0 | |
| RB007 | Ovarian cancer | None | PD | 35.0 | |
| RB008 | CRC | None | SD | 144.0 | |
| RB009 | Gastric cancer | None | PD | 17.0 | |
| RB010 | CRC | None | PD | 14.0 | |
| RB011 | CRC | None | PD | 32.0 | |
| RB012 | Melanoma | None | SD | 156.0 | |
| RB013 | CRC | None | SD | 99.0 | |
| RB014 | CRC | None | SD | 92.0 | |
| RB015 | Melanoma | None | PD | 44.0 | |
| RB016 | Sarcoma | None | PD | 15.0 | |
| RB017 | Sebaceous carcinoma | None | SD | 100.0 |
CRC, colorectal cancer; DLT, dose-limiting toxicity; PD, progressive disease; SD, stable disease.